Sie können mich auf folgenden Wegen kontaktieren:

  • Englisch
  • Deutsch

E-Mail : mail@gefaesschirurg-wien.at
  Tel. : +43 699 11436667

Publikationsliste

Originalarbeiten Journalimpactfactor/ times cited

  1. Eilenberg W, Stojkovic S, Piechota-Polanczyk A, Kaun C, Rauscher S, Gröger M, Klinger M, Wojta J, Neumayer C, Huk I, Demyanets S. Neutrophil Gelatinase-Associated Lipocalin (NGAL) is Associated with Symptomatic Carotid Atherosclerosis and Drives Pro-inflammatory State In Vitro. Eur J Vasc Endovasc Surg. (2016) 51: 623-31.
  2. Piechota-Polanczyk A, Demyanets S, Mittlboeck M, Hofmann M, Domenig CM, Neumayer C, Wojta J, Klinger M, Nanobachvili J, Huk I. The Influence of Simvastatin on NGAL, Matrix Metalloproteinases and Their Tissue Inhibitors in Human Intraluminal Thrombus and Abdominal Aortic Aneurysm Tissue.
    Eur J Vasc Endovasc Surg. (2015) 49: 549-55.
  3. Piechota-Polanczyk A, Demyanets S, Mittlboeck M, Hofmann M, Domenig CM, Neumayer C, Wojta J, Klinger M, Nanobachvili J, Huk I. The Influence of Simvastatin on NGAL, Matrix Metalloproteinases and Their Tissue Inhibitors in Human Intraluminal Thrombus and Abdominal Aortic Aneurysm Tissue.
    Eur J Vasc Endovasc Surg. (2015) 49: 549-55. 3.0/ 0
  4. Piechota-Polanczyk A, Demyanets S, Nykonenko O, Huk I, Mittlboeck M, Domenig CM, Neumayer C, Wojta J, Nanobachvili J, Klinger M. Decreased tissue levels of cyclophilin A, a cyclosporine a target and phospho-ERK1/2 in simvastatin patients with abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. (2013) 45: 682-8. 3.0/ 2
  5. Piechota-Polanczyk A, Goraca A, Demyanets S, Mittlboeck M, Domenig C, Neumayer C, Wojta J, Nanobachvili J, Huk I, Klinger M. Simvastatin decreases free radicals formation in the human abdominal aortic aneurysm wall via NF-κB. Eur J Vasc Endovasc Surg. (2012) 44 :133-7. 3.0/15
  6. Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B,Gruenberger T. Sinusoidal obstruction syndrome impairs long-term outcome ofcolorectal liver metastases treated with resection after neoadjuvantchemotherapy. Ann Surg Oncol. (2011) 18: 421-30. 3.9/45
  7. Tamandl D, Gruenberger B, Klinger M, Herberger B, Kaczirek K, Fleischmann E, Gruenberger T. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Ann Surg. (2010) 252:124-30. 7.1/48
  8. Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, Dorfmeister M, Gruenberger B, Gruenberger T. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol. (2010) 17: 2059-65.3.9/32
  9. Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, Koelblinger C, Gruenberger B, Gruenberger T. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. (2009) 35: 515-20 2.8/78
  10. Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol. (2008) 15: 2787-94. 3.9/48
  11. Kandutsch S*, Klinger M*, Hacker S, Wrba F, Gruenberger B, Gruenberger T. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol. (2008) 34: 1231-6. 2.8/42
    *equally contributed
  12. Hetz H, Hoetzenecker K, Hacker S, Faybik P, Pollreisz A, Moser B, Roth G, Hoetzenecker W, Lichtenauer M, Klinger M, Krenn CG, Ankersmit HJ. Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration. J Clin Lab Anal. (2007) 21: 277-81. 1.1/16
  13. Farhan H, Schuster C, Klinger M, Weisz E, Waxenecker G, Schuster M, Sexl V, Mudde GC, Freissmuth M, Kircheis R. Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen. J Pharmacol Exp Ther. (2006) 319: 1459-66. 3.8/18
  14. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E.Vaccination with cetuximab mimotopes and biological properties of inducedanti-epidermal growth factor receptor antibodies. J Natl Cancer Inst. (2005) 97: 1663-70. 15.1/57
  15. Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC, Jensen-Jarolim E. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol. (2004) 173: 394-401. 5.3/71
  16. Klinger M, Farhan H, Just H, Drobny H, Himmler G, Loibner H, Mudde GC, Freissmuth M, Sexl V. Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res. (2004) 64: 1087-93. 9.2/42
  17. Kudlacek O, Just H, Korkhov VM, Vartian N, Klinger M, Pankevych H, Yang Q,Nanoff C, Freissmuth M, Boehm S. The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. Neuropsychopharmacology. (2003) 28: 1317-27. 7.8/32
  18. Klinger M, Kuhn M, Just H, Stefan E, Palmer T, Freissmuth M, Nanoff C. Removal of the carboxy terminus of the A2A-adenosine receptor blunts constitutive activity: differential effect on cAMP accumulation and MAP kinase stimulation. Naunyn Schmiedebergs Arch Pharmacol. (2002) 366: 287-98. 2.5/33
  19. Klinger M, Kudlacek O, Seidel MG, Freissmuth M, Sexl V. MAP kinase stimulation by cAMP does not require RAP1 but SRC family kinases. J Biol Chem. (2002) 277: 32490-7. 4.6/63
  20. Klinger M, Bofill-Cardona E, Mayer B, Nanoff C, Freissmuth M, Hohenegger M. Suramin and the suramin analogue NF307 discriminate among calmodulin-binding sites. Biochem J. (2001) 355: 827-33. 4.7/21
  21. Seidel MG, Klinger M, Freissmuth M, Höller C. Activation of mitogen-activated protein kinase by the A(2A)-adenosine receptor via a rap1-dependent and via a p21(ras)-dependent pathway. J Biol Chem. (1999) 274: 25833-41. 4.6/99
  22. Klinger M, Freissmuth M, Nickel P, Stäbler-Schwarzbart M, Kassack M, Suko J, Hohenegger M. Suramin and suramin analogs activate skeletal muscle ryanodine receptor via a calmodulin binding site. Mol Pharmacol. (1999) 55: 462-72. 4.1/28

Übersichtsarbeiten:

Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal. (2002) 14: 99-108. 4.4/171

Buchbeiträge/Patente:

M. Klinger, M. G. Seidel, C. Höller, M. Platzer and M. Freissmuth. Activation of MAP Kinase by the A2A-Adenosine Receptor. Molecular Mechanisms of Signal Transduction. J.L. Bos, ed. (NATO Science Series Press, Amsterdam, ISBN 1 58603 016 7)

Preparation based on an antibody directed against a tumor-associated glycosylation such as lewis structures, Juni 2004 PCT/EP2003/006912